Does the media refer more to PTCT or UTHR?

In the previous week, United Therapeutics had 24 more articles in the media than PTC Therapeutics. MarketBeat recorded 33 mentions for United Therapeutics and 9 mentions for PTC Therapeutics. United Therapeutics' average media sentiment score of 0.68 beat PTC Therapeutics' score of 0.47 indicating that United Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment PTC Therapeutics 4 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral United Therapeutics 14 Very Positive mention(s) 7 Positive mention(s) 6 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is MRNA or PTCT more profitable?

PTC Therapeutics has a net margin of -3.80% compared to Moderna's net margin of -141.43%. Moderna's return on equity of -28.30% beat PTC Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Moderna -141.43% -28.30% -19.39% PTC Therapeutics -3.80% -362.45% -1.32%

Does the media prefer MRNA or PTCT?

In the previous week, Moderna had 48 more articles in the media than PTC Therapeutics. MarketBeat recorded 57 mentions for Moderna and 9 mentions for PTC Therapeutics. Moderna's average media sentiment score of 0.49 beat PTC Therapeutics' score of 0.47 indicating that Moderna is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Moderna 21 Very Positive mention(s) 8 Positive mention(s) 16 Neutral mention(s) 7 Negative mention(s) 0 Very Negative mention(s) Neutral PTC Therapeutics 4 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Is INSM or PTCT more profitable?

PTC Therapeutics has a net margin of -3.80% compared to Insmed's net margin of -76.94%. Insmed's return on equity of -123.94% beat PTC Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Insmed -76.94% -123.94% -44.30% PTC Therapeutics -3.80% -362.45% -1.32%

Does the media prefer INSM or PTCT?

In the previous week, Insmed had 14 more articles in the media than PTC Therapeutics. MarketBeat recorded 23 mentions for Insmed and 9 mentions for PTC Therapeutics. Insmed's average media sentiment score of 0.70 beat PTC Therapeutics' score of 0.47 indicating that Insmed is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Insmed 8 Very Positive mention(s) 4 Positive mention(s) 7 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive PTC Therapeutics 4 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Is GMAB or PTCT more profitable?

Genmab A/S has a net margin of 19.08% compared to PTC Therapeutics' net margin of -3.80%. Genmab A/S's return on equity of 14.89% beat PTC Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Genmab A/S 19.08% 14.89% 7.73% PTC Therapeutics -3.80% -362.45% -1.32%

Does the media favor GMAB or PTCT?

In the previous week, Genmab A/S had 5 more articles in the media than PTC Therapeutics. MarketBeat recorded 14 mentions for Genmab A/S and 9 mentions for PTC Therapeutics. Genmab A/S's average media sentiment score of 0.53 beat PTC Therapeutics' score of 0.47 indicating that Genmab A/S is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Genmab A/S 3 Very Positive mention(s) 2 Positive mention(s) 5 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive PTC Therapeutics 4 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media refer more to PTCT or BBIO?

In the previous week, PTC Therapeutics had 1 more articles in the media than BridgeBio Pharma. MarketBeat recorded 9 mentions for PTC Therapeutics and 8 mentions for BridgeBio Pharma. BridgeBio Pharma's average media sentiment score of 0.87 beat PTC Therapeutics' score of 0.47 indicating that BridgeBio Pharma is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment PTC Therapeutics 4 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral BridgeBio Pharma 6 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

PTC Therapeutics (PTCT) Competitors

$73.31 0.00 (0.00%)

Closing price 08/7/2026 04:00 PM Eastern

Extended Trading

$73.97 +0.66 (+0.90%)

As of 09:07 AM Eastern

Compare

PTCT vs. UTHR, MRNA, INSM, GMAB, and BBIO

Should you buy PTC Therapeutics stock or one of its competitors? MarketBeat compares PTC Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with PTC Therapeutics include United Therapeutics (UTHR), Moderna (MRNA), Insmed (INSM), Genmab A/S (GMAB), and BridgeBio Pharma (BBIO). These companies are all part of the "biotechnology" industry.

How does PTC Therapeutics compare to United Therapeutics?

PTC Therapeutics (NASDAQ:PTCT) and United Therapeutics (NASDAQ:UTHR) are both healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their dividends, risk, analyst recommendations, profitability, earnings, media sentiment, institutional ownership and valuation.

PTC Therapeutics currently has a consensus price target of $98.09, indicating a potential upside of 33.80%. United Therapeutics has a consensus price target of $646.00, indicating a potential upside of 19.89%. Given PTC Therapeutics' higher possible upside, equities analysts clearly believe PTC Therapeutics is more favorable than United Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
PTC Therapeutics	2 Sell rating(s)	2 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.64
United Therapeutics	0 Sell rating(s)	2 Hold rating(s)	11 Buy rating(s)	0 Strong Buy rating(s)	2.85

United Therapeutics has higher revenue and earnings than PTC Therapeutics. PTC Therapeutics is trading at a lower price-to-earnings ratio than United Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
PTC Therapeutics	$1.73B	3.54	$682.64M	-$0.58	N/A
United Therapeutics	$3.18B	7.26	$1.33B	$27.95	19.28

PTC Therapeutics has a beta of 0.56, indicating that its share price is 44% less volatile than the broader market. Comparatively, United Therapeutics has a beta of 0.59, indicating that its share price is 41% less volatile than the broader market.

94.1% of United Therapeutics shares are owned by institutional investors. 5.3% of PTC Therapeutics shares are owned by company insiders. Comparatively, 8.6% of United Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

In the previous week, United Therapeutics had 24 more articles in the media than PTC Therapeutics. MarketBeat recorded 33 mentions for United Therapeutics and 9 mentions for PTC Therapeutics. United Therapeutics' average media sentiment score of 0.68 beat PTC Therapeutics' score of 0.47 indicating that United Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
PTC Therapeutics	4 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
United Therapeutics	14 Very Positive mention(s)	7 Positive mention(s)	6 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

United Therapeutics has a net margin of 41.56% compared to PTC Therapeutics' net margin of -3.80%. United Therapeutics' return on equity of 20.18% beat PTC Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
PTC Therapeutics	-3.80%	-362.45%	-1.32%
United Therapeutics	41.56%	20.18%	17.98%

Summary

United Therapeutics beats PTC Therapeutics on 15 of the 17 factors compared between the two stocks.

How does PTC Therapeutics compare to Moderna?

Moderna (NASDAQ:MRNA) and PTC Therapeutics (NASDAQ:PTCT) are both healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their risk, institutional ownership, profitability, dividends, valuation, analyst recommendations, earnings and media sentiment.

Moderna currently has a consensus target price of $42.13, indicating a potential downside of 28.79%. PTC Therapeutics has a consensus target price of $98.09, indicating a potential upside of 33.80%. Given PTC Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe PTC Therapeutics is more favorable than Moderna.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Moderna	5 Sell rating(s)	9 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	1.88
PTC Therapeutics	2 Sell rating(s)	2 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.64

Moderna has a beta of 0.91, meaning that its share price is 9% less volatile than the broader market. Comparatively, PTC Therapeutics has a beta of 0.56, meaning that its share price is 44% less volatile than the broader market.

In the previous week, Moderna had 48 more articles in the media than PTC Therapeutics. MarketBeat recorded 57 mentions for Moderna and 9 mentions for PTC Therapeutics. Moderna's average media sentiment score of 0.49 beat PTC Therapeutics' score of 0.47 indicating that Moderna is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Moderna	21 Very Positive mention(s)	8 Positive mention(s)	16 Neutral mention(s)	7 Negative mention(s)	0 Very Negative mention(s)	Neutral
PTC Therapeutics	4 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

PTC Therapeutics has lower revenue, but higher earnings than Moderna. PTC Therapeutics is trading at a lower price-to-earnings ratio than Moderna, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Moderna	$1.94B	12.15	-$2.82B	-$7.99	N/A
PTC Therapeutics	$1.73B	3.54	$682.64M	-$0.58	N/A

PTC Therapeutics has a net margin of -3.80% compared to Moderna's net margin of -141.43%. Moderna's return on equity of -28.30% beat PTC Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Moderna	-141.43%	-28.30%	-19.39%
PTC Therapeutics	-3.80%	-362.45%	-1.32%

75.3% of Moderna shares are owned by institutional investors. 10.8% of Moderna shares are owned by insiders. Comparatively, 5.3% of PTC Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Summary

Moderna beats PTC Therapeutics on 9 of the 17 factors compared between the two stocks.

How does PTC Therapeutics compare to Insmed?

Insmed (NASDAQ:INSM) and PTC Therapeutics (NASDAQ:PTCT) are both healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their risk, institutional ownership, dividends, profitability, media sentiment, analyst recommendations, earnings and valuation.

Insmed has a beta of 0.81, meaning that its share price is 19% less volatile than the broader market. Comparatively, PTC Therapeutics has a beta of 0.56, meaning that its share price is 44% less volatile than the broader market.

In the previous week, Insmed had 14 more articles in the media than PTC Therapeutics. MarketBeat recorded 23 mentions for Insmed and 9 mentions for PTC Therapeutics. Insmed's average media sentiment score of 0.70 beat PTC Therapeutics' score of 0.47 indicating that Insmed is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Insmed	8 Very Positive mention(s)	4 Positive mention(s)	7 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
PTC Therapeutics	4 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

PTC Therapeutics has a net margin of -3.80% compared to Insmed's net margin of -76.94%. Insmed's return on equity of -123.94% beat PTC Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Insmed	-76.94%	-123.94%	-44.30%
PTC Therapeutics	-3.80%	-362.45%	-1.32%

Insmed presently has a consensus price target of $205.26, indicating a potential upside of 56.57%. PTC Therapeutics has a consensus price target of $98.09, indicating a potential upside of 33.80%. Given Insmed's stronger consensus rating and higher probable upside, equities analysts plainly believe Insmed is more favorable than PTC Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Insmed	1 Sell rating(s)	0 Hold rating(s)	23 Buy rating(s)	2 Strong Buy rating(s)	3.00
PTC Therapeutics	2 Sell rating(s)	2 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.64

PTC Therapeutics has higher revenue and earnings than Insmed. PTC Therapeutics is trading at a lower price-to-earnings ratio than Insmed, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Insmed	$1.14B	24.98	-$1.28B	-$4.11	N/A
PTC Therapeutics	$1.73B	3.54	$682.64M	-$0.58	N/A

Summary

Insmed beats PTC Therapeutics on 10 of the 15 factors compared between the two stocks.

How does PTC Therapeutics compare to Genmab A/S?

Genmab A/S (NASDAQ:GMAB) and PTC Therapeutics (NASDAQ:PTCT) are both healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their profitability, institutional ownership, media sentiment, dividends, risk, analyst recommendations, earnings and valuation.

7.1% of Genmab A/S shares are held by institutional investors. 1.5% of Genmab A/S shares are held by insiders. Comparatively, 5.3% of PTC Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

In the previous week, Genmab A/S had 5 more articles in the media than PTC Therapeutics. MarketBeat recorded 14 mentions for Genmab A/S and 9 mentions for PTC Therapeutics. Genmab A/S's average media sentiment score of 0.53 beat PTC Therapeutics' score of 0.47 indicating that Genmab A/S is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Genmab A/S	3 Very Positive mention(s)	2 Positive mention(s)	5 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
PTC Therapeutics	4 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Genmab A/S has a net margin of 19.08% compared to PTC Therapeutics' net margin of -3.80%. Genmab A/S's return on equity of 14.89% beat PTC Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Genmab A/S	19.08%	14.89%	7.73%
PTC Therapeutics	-3.80%	-362.45%	-1.32%

Genmab A/S has higher revenue and earnings than PTC Therapeutics. PTC Therapeutics is trading at a lower price-to-earnings ratio than Genmab A/S, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Genmab A/S	$3.72B	5.24	$963M	$1.27	24.61
PTC Therapeutics	$1.73B	3.54	$682.64M	-$0.58	N/A

Genmab A/S has a beta of 0.83, indicating that its stock price is 17% less volatile than the broader market. Comparatively, PTC Therapeutics has a beta of 0.56, indicating that its stock price is 44% less volatile than the broader market.

Genmab A/S currently has a consensus price target of $39.50, indicating a potential upside of 26.40%. PTC Therapeutics has a consensus price target of $98.09, indicating a potential upside of 33.80%. Given PTC Therapeutics' higher possible upside, analysts clearly believe PTC Therapeutics is more favorable than Genmab A/S.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Genmab A/S	0 Sell rating(s)	3 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.85
PTC Therapeutics	2 Sell rating(s)	2 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.64

Summary

Genmab A/S beats PTC Therapeutics on 13 of the 15 factors compared between the two stocks.

How does PTC Therapeutics compare to BridgeBio Pharma?

PTC Therapeutics (NASDAQ:PTCT) and BridgeBio Pharma (NASDAQ:BBIO) are both healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their institutional ownership, risk, media sentiment, analyst recommendations, profitability, dividends, valuation and earnings.

PTC Therapeutics has a beta of 0.56, indicating that its stock price is 44% less volatile than the broader market. Comparatively, BridgeBio Pharma has a beta of 0.96, indicating that its stock price is 4% less volatile than the broader market.

In the previous week, PTC Therapeutics had 1 more articles in the media than BridgeBio Pharma. MarketBeat recorded 9 mentions for PTC Therapeutics and 8 mentions for BridgeBio Pharma. BridgeBio Pharma's average media sentiment score of 0.87 beat PTC Therapeutics' score of 0.47 indicating that BridgeBio Pharma is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
PTC Therapeutics	4 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
BridgeBio Pharma	6 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

PTC Therapeutics has higher revenue and earnings than BridgeBio Pharma. PTC Therapeutics is trading at a lower price-to-earnings ratio than BridgeBio Pharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
PTC Therapeutics	$1.73B	3.54	$682.64M	-$0.58	N/A
BridgeBio Pharma	$502.08M	32.89	-$724.93M	-$3.74	N/A

PTC Therapeutics has a net margin of -3.80% compared to BridgeBio Pharma's net margin of -124.42%. BridgeBio Pharma's return on equity of 0.00% beat PTC Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
PTC Therapeutics	-3.80%	-362.45%	-1.32%
BridgeBio Pharma	-124.42%	N/A	-65.81%

99.9% of BridgeBio Pharma shares are held by institutional investors. 5.3% of PTC Therapeutics shares are held by company insiders. Comparatively, 14.2% of BridgeBio Pharma shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

PTC Therapeutics currently has a consensus price target of $98.09, indicating a potential upside of 33.80%. BridgeBio Pharma has a consensus price target of $97.33, indicating a potential upside of 15.21%. Given PTC Therapeutics' higher possible upside, research analysts plainly believe PTC Therapeutics is more favorable than BridgeBio Pharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
PTC Therapeutics	2 Sell rating(s)	2 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.64
BridgeBio Pharma	1 Sell rating(s)	2 Hold rating(s)	19 Buy rating(s)	0 Strong Buy rating(s)	2.82

Summary

BridgeBio Pharma beats PTC Therapeutics on 9 of the 17 factors compared between the two stocks.

Get PTC Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding PTCT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

PTCT vs. The Competition

Export

Metric	PTC Therapeutics	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$6.12B	$3.69B	$7.00B	$12.99B
Dividend Yield	N/A	3.76%	2.58%	10.20%
P/E Ratio	-126.40	9.02	270.57	25.05
Price / Sales	3.54	1,291.29	659.56	107.93
Price / Cash	8.35	44.95	28.89	37.44
Price / Book	-28.64	17.52	11.20	6.43
Net Income	$682.64M	-$13.25M	$3.45B	$348.10M
7 Day Performance	7.63%	5.02%	3.39%	2.66%
1 Month Performance	-13.60%	-2.12%	-0.72%	-0.85%
1 Year Performance	61.55%	61.49%	77.42%	23.96%

PTC Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
PTCT PTC Therapeutics	4.134 of 5 stars	$73.31 flat	$98.09 +33.8%	+61.5%	$6.12B	$1.73B	N/A	1,410
UTHR United Therapeutics	4.4315 of 5 stars	$516.31 -0.3%	$648.33 +25.6%	+78.7%	$21.98B	$3.18B	19.06	1,400	Trending News Earnings Report
MRNA Moderna	1.3628 of 5 stars	$55.14 +0.6%	$42.13 -23.6%	+126.5%	$21.75B	$1.94B	N/A	4,700	Gap Down
INSM Insmed	3.8251 of 5 stars	$98.45 -0.2%	$209.35 +112.6%	+19.7%	$21.37B	$819.56M	N/A	1,664	Trending News Earnings Report Analyst Forecast Gap Up
GMAB Genmab A/S	4.7165 of 5 stars	$28.68 -0.7%	$39.28 +37.0%	+45.8%	$18.00B	$3.72B	21.73	3,029	Positive News Earnings Report Analyst Forecast

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:PTCT) was last updated on 8/10/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

PTC Therapeutics (PTCT) Competitors

PTCT vs. UTHR, MRNA, INSM, GMAB, and BBIO

How does PTC Therapeutics compare to United Therapeutics?

Summary

How does PTC Therapeutics compare to Moderna?

Summary

How does PTC Therapeutics compare to Insmed?

Summary

How does PTC Therapeutics compare to Genmab A/S?

Summary

How does PTC Therapeutics compare to BridgeBio Pharma?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PTCT vs. The Competition

PTC Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

PTC Therapeutics (PTCT) Competitors

PTCT vs. UTHR, MRNA, INSM, GMAB, and BBIO

How does PTC Therapeutics compare to United Therapeutics?

Do analysts rate PTCT or UTHR?

Which has preferable valuation & earnings, PTCT or UTHR?

Which has more volatility & risk, PTCT or UTHR?

Do insiders and institutionals have more ownership in PTCT or UTHR?

Does the media refer more to PTCT or UTHR?

Is PTCT or UTHR more profitable?

Summary

How does PTC Therapeutics compare to Moderna?

Do analysts prefer MRNA or PTCT?

Which has more risk and volatility, MRNA or PTCT?

Does the media prefer MRNA or PTCT?

Which has preferable earnings & valuation, MRNA or PTCT?

Is MRNA or PTCT more profitable?

Do institutionals and insiders believe in MRNA or PTCT?

Summary

How does PTC Therapeutics compare to Insmed?

Which has more volatility & risk, INSM or PTCT?

Does the media prefer INSM or PTCT?

Is INSM or PTCT more profitable?

Do analysts prefer INSM or PTCT?

Which has stronger valuation & earnings, INSM or PTCT?

Summary

How does PTC Therapeutics compare to Genmab A/S?

Do institutionals and insiders believe in GMAB or PTCT?

Does the media favor GMAB or PTCT?

Is GMAB or PTCT more profitable?

Which has stronger earnings and valuation, GMAB or PTCT?

Which has more volatility & risk, GMAB or PTCT?

Do analysts rate GMAB or PTCT?

Summary

How does PTC Therapeutics compare to BridgeBio Pharma?

Which has more volatility and risk, PTCT or BBIO?

Does the media refer more to PTCT or BBIO?

Which has better earnings and valuation, PTCT or BBIO?

Is PTCT or BBIO more profitable?

Do institutionals & insiders have more ownership in PTCT or BBIO?

Do analysts rate PTCT or BBIO?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PTCT vs. The Competition

PTC Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools